(Q40477055)

English

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo (English)
A Rodríguez-Lescure
C Fernandez-Chacón
P Martínez del Prado
J M López-Vega

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit